Compare GSK plc (GSK) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Huntington Bancshares Incorporated — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Huntington Bancshares Incorporated trades at $15.31 (market cap $31.04B). The key difference: GSK plc is far larger — about 3× Huntington Bancshares Incorporated's market cap, and Huntington Bancshares Incorporated pays the higher dividend (4.04%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Huntington Bancshares Incorporated for 52 Days on average.
| GSK | HBAN | |
|---|---|---|
Market Cap | $91.88B | $31.04B |
Volume | 7,730,529 | 23,864,172 |
Sector | Health | Financials |
52-Week High | $61.18 | $19.27 |
52-Week Low | $43.24 | $15.02 |
Typical Hold Time | 93 Days | 52 Days |
Enterprise Value | $111.88B | $49.57B |
Dividend Yield | 3.9% | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Huntington Bancshares (HBAN) trades at $15.32, up 0.99% on the day, with a bearish technical signal and mixed earnings history. The company reported 2025 revenue of $8.13B and net income of $2.21B, with a P/E of 11.82 and ROE of 9.23%. Recent news highlights an increased prime rate to 7.00% and a revised 2027 earnings outlook due to margin pressures.
Outlook is cautious; analyst consensus is a Buy with a $19.60 price target, but near-term headwinds from higher interest rates and deposit costs pose risks. The stock offers value based on valuation metrics, yet investors should weigh margin pressures against shareholder return initiatives like the $550M buyback plan for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
